{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,19]],"date-time":"2026-08-19T18:21:41Z","timestamp":1787163701377,"version":"build-2736575974"},"reference-count":26,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,12,19]],"date-time":"2025-12-19T00:00:00Z","timestamp":1766102400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2025,12,19]],"date-time":"2025-12-19T00:00:00Z","timestamp":1766102400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"funder":[{"name":"the Foundation of Science and Technology Bureau of Xiamen","award":["3502Z20224ZD1082"],"award-info":[{"award-number":["3502Z20224ZD1082"]}]},{"DOI":"10.13039\/100016966","name":"Bethune Charitable Foundation","doi-asserted-by":"publisher","award":["BCF-MSD-HCC-20201127-001"],"award-info":[{"award-number":["BCF-MSD-HCC-20201127-001"]}],"id":[{"id":"10.13039\/100016966","id-type":"DOI","asserted-by":"publisher"}]},{"name":"the Natural Science Foundation Project of Xiamen","award":["3502Z20227386"],"award-info":[{"award-number":["3502Z20227386"]}]},{"name":"the Foundation of the Natural Science Foundation of Fujian Province","award":["2022J011428"],"award-info":[{"award-number":["2022J011428"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Cancer Immunol Immunother"],"DOI":"10.1007\/s00262-025-04255-1","type":"journal-article","created":{"date-parts":[[2025,12,19]],"date-time":"2025-12-19T06:22:50Z","timestamp":1766125370000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["Efficacy and safety of hepatic arterial infusion chemotherapy plus lenvatinib and PD-1\/PD-L1 inhibitors versus systemic chemotherapy plus lenvatinib and PD-1\/PD-L1 inhibitors in advanced unresectable cholangiocarcinoma: a retrospective cohort study"],"prefix":"10.1007","volume":"75","author":[{"given":"Zhenzhen","family":"Zhang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Meixia","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Guobin","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yanfang","family":"Wu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaochun","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xinkun","family":"Guo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Boheng","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,12,19]]},"reference":[{"key":"4255_CR1","doi-asserted-by":"publisher","first-page":"626","DOI":"10.1097\/HEP.0000000000001200","volume":"82","author":"QT Vu","year":"2025","unstructured":"Vu QT, Nishimura Y, Harada K, Ito H, Higashionna T, Maruo A et al (2025) International trends in biliary tract cancer-related mortality, 2000\u20132022: an observational study of the world health organization mortality database. Hepatology 82:626\u2013637. https:\/\/doi.org\/10.1097\/HEP.0000000000001200","journal-title":"Hepatology"},{"key":"4255_CR2","doi-asserted-by":"publisher","first-page":"470","DOI":"10.1038\/s41571-023-00770-1","volume":"20","author":"SI Ilyas","year":"2023","unstructured":"Ilyas SI, Affo S, Goyal L, Lamarca A, Sapisochin G, Yang JD et al (2023) Cholangiocarcinoma - novel biological insights and therapeutic strategies. Nat Rev Clin Oncol 20:470\u2013486. https:\/\/doi.org\/10.1038\/s41571-023-00770-1","journal-title":"Nat Rev Clin Oncol"},{"key":"4255_CR3","doi-asserted-by":"publisher","first-page":"694","DOI":"10.6004\/jnccn.2023.0035","volume":"21","author":"AB Benson","year":"2023","unstructured":"Benson AB, D\u2019Angelica MI, Abrams T, Abbott DE, Ahmed A, Anaya DA et al (2023) NCCN guidelines(r) insights: biliary tract cancers, version 2.2023. J Natl Compr Canc Netw 21:694\u2013704. https:\/\/doi.org\/10.6004\/jnccn.2023.0035","journal-title":"J Natl Compr Canc Netw"},{"key":"4255_CR4","doi-asserted-by":"publisher","first-page":"788","DOI":"10.1093\/annonc\/mdz058","volume":"30","author":"ST Kim","year":"2019","unstructured":"Kim ST, Kang JH, Lee J, Lee HW, Oh SY, Jang JS et al (2019) Capecitabine plus oxaliplatin versus gemcitabine plus oxaliplatin as first-line therapy for advanced biliary tract cancers: a multicenter, open-label, randomized, phase III, noninferiority trial. Ann Oncol 30:788\u2013795. https:\/\/doi.org\/10.1093\/annonc\/mdz058","journal-title":"Ann Oncol"},{"key":"4255_CR5","doi-asserted-by":"publisher","first-page":"626","DOI":"10.1016\/S1470-2045(24)00082-2","volume":"25","author":"HAR Burris","year":"2024","unstructured":"Burris HAR, Okusaka T, Vogel A, Lee MA, Takahashi H, Breder V et al (2024) Durvalumab plus gemcitabine and cisplatin in advanced biliary tract cancer (TOPAZ-1): patient-reported outcomes from a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet Oncol 25:626\u2013635. https:\/\/doi.org\/10.1016\/S1470-2045(24)00082-2","journal-title":"Lancet Oncol"},{"key":"4255_CR6","doi-asserted-by":"publisher","first-page":"1853","DOI":"10.1016\/S0140-6736(23)00727-4","volume":"401","author":"M Ueno","year":"2023","unstructured":"Ueno M, Finn RS, Ren Z, Yau T, Kl\u00fcmpen H, Chan SL et al (2023) Pembrolizumab in combination with gemcitabine and cisplatin compared with gemcitabine and cisplatin alone for patients with advanced biliary tract cancer (KEYNOTE-966): a randomised, double-blind, placebo-controlled, phase 3 trial. The Lancet (British edition) 401:1853\u20131865. https:\/\/doi.org\/10.1016\/S0140-6736(23)00727-4","journal-title":"The Lancet (British edition)"},{"key":"4255_CR7","doi-asserted-by":"publisher","first-page":"3371","DOI":"10.1158\/1078-0432.CCR-24-0517","volume":"30","author":"SJ Casak","year":"2024","unstructured":"Casak SJ, Kumar V, Song C, Yuan M, Amatya AK, Cheng J et al (2024) FDA approval summary: durvalumab and pembrolizumab, immune checkpoint inhibitors for the treatment of biliary tract cancer. Clin Cancer Res 30:3371\u20133377. https:\/\/doi.org\/10.1158\/1078-0432.CCR-24-0517","journal-title":"Clin Cancer Res"},{"key":"4255_CR8","doi-asserted-by":"publisher","first-page":"23961","DOI":"10.1038\/s41598-024-75102-z","volume":"14","author":"Z Lin","year":"2024","unstructured":"Lin Z, Zou X, Hu X, Huang D, Chen Y, Lin J et al (2024) Efficacy analysis of HAIC combined with lenvatinib plus PD-1 inhibitor vs. first-line systemic chemotherapy for advanced intrahepatic cholangiocarcinoma. Sci Rep 14:23961. https:\/\/doi.org\/10.1038\/s41598-024-75102-z","journal-title":"Sci Rep"},{"key":"4255_CR9","doi-asserted-by":"publisher","first-page":"111642","DOI":"10.1016\/j.intimp.2024.111642","volume":"129","author":"T Zhang","year":"2024","unstructured":"Zhang T, Zhu C, Zhang N, Zhang L, Wang S, Xun Z et al (2024) Lenvatinib combined with PD-1 inhibitor plus gemox chemotherapy versus plus HAIC for advanced biliary tract cancer. Int Immunopharmacol 129:111642. https:\/\/doi.org\/10.1016\/j.intimp.2024.111642","journal-title":"Int Immunopharmacol"},{"key":"4255_CR10","doi-asserted-by":"publisher","first-page":"1286","DOI":"10.5582\/bst.2024.01286","volume":"18","author":"Z Sun","year":"2024","unstructured":"Sun Z, Xu H, Yang L, Wang X, Shu B, Yang M et al (2024) MFOLFOX-HAIC+lenvatinib+PD-1 inhibitors versus GC\/GS\/GEMOX chemotherapy as a first line therapy for advanced biliary tract cancer: a single-center retrospective cohort study. Biosci Trends 18:1286\u20132024. https:\/\/doi.org\/10.5582\/bst.2024.01286","journal-title":"Biosci Trends"},{"key":"4255_CR11","doi-asserted-by":"publisher","first-page":"1552","DOI":"10.1097\/JS9.0000000000002013","volume":"111","author":"Z Zheng","year":"2025","unstructured":"Zheng Z, Wang J, Wu T, He M, Pan Y, Wang J et al (2025) Hepatic arterial infusion chemotherapy plus targeted therapy and immunotherapy versus systemic chemotherapy for advanced intrahepatic cholangiocarcinoma: a retrospective cohort study. Int J Surg 111:1552\u20131557. https:\/\/doi.org\/10.1097\/JS9.0000000000002013","journal-title":"Int J Surg"},{"key":"4255_CR12","doi-asserted-by":"publisher","DOI":"10.1016\/j.xcrm.2025.102298","author":"R Xing","year":"2025","unstructured":"Xing R, Mei J, Zuo Z, Zou H, Yu X, Xu J et al (2025) Enhanced formation of tertiary lymphoid structures shapes the anti-tumor microenvironment in hepatocellular carcinoma after FOLFOX-HAIC therapy. Cell Rep Med. https:\/\/doi.org\/10.1016\/j.xcrm.2025.102298","journal-title":"Cell Rep Med"},{"key":"4255_CR13","doi-asserted-by":"publisher","first-page":"1260191","DOI":"10.3389\/fimmu.2024.1260191","volume":"15","author":"Y Huang","year":"2024","unstructured":"Huang Y, Du Z, Kan A, He M, Li H, Lai Z et al (2024) Clinical and biomarker analyses of hepatic arterial infusion chemotherapy plus lenvatinib and PD-1 inhibitor for patients with advanced intrahepatic cholangiocarcinoma. Front Immunol 15:1260191. https:\/\/doi.org\/10.3389\/fimmu.2024.1260191","journal-title":"Front Immunol"},{"key":"4255_CR14","doi-asserted-by":"publisher","first-page":"338","DOI":"10.1186\/s12964-024-01711-w","volume":"22","author":"M Yang","year":"2024","unstructured":"Yang M, Cui M, Sun Y, Liu S, Jiang W (2024) Mechanisms, combination therapy, and biomarkers in cancer immunotherapy resistance. Cell Commun Signal 22:338. https:\/\/doi.org\/10.1186\/s12964-024-01711-w","journal-title":"Cell Commun Signal"},{"key":"4255_CR15","doi-asserted-by":"publisher","first-page":"1640970","DOI":"10.3389\/fimmu.2025.1640970","volume":"16","author":"D Zeng","year":"2025","unstructured":"Zeng D, Cheng Z, Liu G, Lu J, Li B (2025) Hepatic arterial infusion chemotherapy versus systemic chemotherapy for advanced intrahepatic cholangiocarcinoma: a meta-analysis of survival outcomes. Front Immunol 16:1640970. https:\/\/doi.org\/10.3389\/fimmu.2025.1640970","journal-title":"Front Immunol"},{"key":"4255_CR16","doi-asserted-by":"publisher","first-page":"228","DOI":"10.1016\/j.ejca.2008.10.026","volume":"45","author":"EA Eisenhauer","year":"2009","unstructured":"Eisenhauer EA, Therasse P, Bogaerts J, Schwartz LH, Sargent D, Ford R et al (2009) New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1). Eur J Cancer 45:228\u2013247. https:\/\/doi.org\/10.1016\/j.ejca.2008.10.026","journal-title":"Eur J Cancer"},{"key":"4255_CR17","doi-asserted-by":"publisher","DOI":"10.1016\/j.jhep.2025.05.003","author":"D Oh","year":"2025","unstructured":"Oh D, He AR, Qin S, Chen L, Okusaka T, Kim JW et al (2025) Durvalumab plus chemotherapy in advanced biliary tract cancer: 3-year overall survival update from the phase III TOPAZ-1 study. J Hepatol. https:\/\/doi.org\/10.1016\/j.jhep.2025.05.003","journal-title":"J Hepatol"},{"key":"4255_CR18","doi-asserted-by":"publisher","first-page":"775","DOI":"10.1007\/s12672-025-02397-3","volume":"16","author":"Q Xu","year":"2025","unstructured":"Xu Q, Wang C, You R, Leng B, Yu Z, Lu Y et al (2025) Hepatic arterial infusion chemotherapy (HAIC) plus lenvatinib and PD-1 inhibitors versus systemic chemotherapy for unresectable intrahepatic cholangiocarcinoma. Discov Oncol 16:775. https:\/\/doi.org\/10.1007\/s12672-025-02397-3","journal-title":"Discov Oncol"},{"key":"4255_CR19","doi-asserted-by":"publisher","first-page":"1808","DOI":"10.1111\/liv.15953","volume":"44","author":"Y Qin","year":"2024","unstructured":"Qin Y, Han S, Yu Y, Qi D, Ran M, Yang M et al (2024) Lenvatinib in hepatocellular carcinoma: resistance mechanisms and strategies for improved efficacy. Liver Int 44:1808\u20131831. https:\/\/doi.org\/10.1111\/liv.15953","journal-title":"Liver Int"},{"key":"4255_CR20","doi-asserted-by":"publisher","first-page":"130","DOI":"10.1186\/s13045-024-01647-1","volume":"17","author":"Y Chen","year":"2024","unstructured":"Chen Y, Dai S, Cheng C, Chen L (2024) Lenvatinib and immune-checkpoint inhibitors in hepatocellular carcinoma: mechanistic insights, clinical efficacy, and future perspectives. J Hematol Oncol 17:130. https:\/\/doi.org\/10.1186\/s13045-024-01647-1","journal-title":"J Hematol Oncol"},{"key":"4255_CR21","doi-asserted-by":"publisher","first-page":"106","DOI":"10.1038\/s41392-023-01317-7","volume":"8","author":"GM Shi","year":"2023","unstructured":"Shi GM, Huang XY, Wu D, Sun HC, Liang F, Ji Y et al (2023) Toripalimab combined with lenvatinib and GEMOX is a promising regimen as first-line treatment for advanced intrahepatic cholangiocarcinoma: a single-center, single-arm, phase 2 study. Signal Transduct Target Ther 8:106. https:\/\/doi.org\/10.1038\/s41392-023-01317-7","journal-title":"Signal Transduct Target Ther"},{"key":"4255_CR22","doi-asserted-by":"publisher","first-page":"1165510","DOI":"10.3389\/fimmu.2023.1165510","volume":"14","author":"J Zhu","year":"2023","unstructured":"Zhu J, Wang D, Liu C, Huang R, Gao F, Feng X et al (2023) Development and validation of a new prognostic immune-inflammatory-nutritional score for predicting outcomes after curative resection for intrahepatic cholangiocarcinoma: a multicenter study. Front Immunol 14:1165510. https:\/\/doi.org\/10.3389\/fimmu.2023.1165510","journal-title":"Front Immunol"},{"key":"4255_CR23","doi-asserted-by":"publisher","first-page":"1117","DOI":"10.21037\/jtd.2019.04.41","volume":"11","author":"Y Ichiki","year":"2019","unstructured":"Ichiki Y, Taira A, Chikaishi Y, Matsumiya H, Mori M, Kanayama M et al (2019) Prognostic factors of advanced or postoperative recurrent non-small cell lung cancer targeted with immune check point inhibitors. J Thorac Dis 11:1117\u20131123. https:\/\/doi.org\/10.21037\/jtd.2019.04.41","journal-title":"J Thorac Dis"},{"key":"4255_CR24","doi-asserted-by":"publisher","first-page":"2512645","DOI":"10.1080\/21645515.2025.2512645","volume":"21","author":"L Xu","year":"2025","unstructured":"Xu L, Chen Y, Xiong L, Shen Y, Zhou Z, Wang S et al (2025) A review of immune checkpoint inhibitor-associated myocarditis: epidemiology, pathogenesis, and biomarkers. Hum Vaccin Immunother 21:2512645. https:\/\/doi.org\/10.1080\/21645515.2025.2512645","journal-title":"Hum Vaccin Immunother"},{"key":"4255_CR25","doi-asserted-by":"publisher","DOI":"10.3390\/biology10040325","author":"D Ravindranathan","year":"2021","unstructured":"Ravindranathan D, Master VA, Bilen MA (2021) Inflammatory markers in cancer immunotherapy. Biology. https:\/\/doi.org\/10.3390\/biology10040325","journal-title":"Biology"},{"key":"4255_CR26","doi-asserted-by":"publisher","first-page":"115435","DOI":"10.1016\/j.ejca.2025.115435","volume":"221","author":"F Monaca","year":"2025","unstructured":"Monaca F, Gomez-Randulfe I, Parreira AS, Longo V, Galetta D, Pilotto S et al (2025) Correlation between irAEs and survival outcomes in patients with ES-SCLC treated with first-line chemoimmunotherapy. Eur J Cancer 221:115435. https:\/\/doi.org\/10.1016\/j.ejca.2025.115435","journal-title":"Eur J Cancer"}],"container-title":["Cancer Immunology, Immunotherapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00262-025-04255-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00262-025-04255-1","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00262-025-04255-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,12,19]],"date-time":"2025-12-19T19:02:21Z","timestamp":1766170941000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00262-025-04255-1"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,12,19]]},"references-count":26,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,1]]}},"alternative-id":["4255"],"URL":"https:\/\/doi.org\/10.1007\/s00262-025-04255-1","relation":{},"ISSN":["1432-0851"],"issn-type":[{"value":"1432-0851","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,12,19]]},"assertion":[{"value":"19 May 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"26 November 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"19 December 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no competing interests.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interests"}},{"value":"The study protocol was reviewed and approved by the Ethics Committee of Xiamen Branch, Zhongshan Hospital, Fudan University (authorization number B2021\u2013002R), and the study was conducted in accordance with good clinical practice guidelines and the tenets of the Declaration of Helsinki, 1964. The requirement of informed consent was waived owing to the retrospective nature of the study.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval"}}],"article-number":"15"}}